Keywords: third, delay, gw, pharmaceuticals, cannabis-based, sativex, uk
Third delay this year for GW Pharmaceuticals cannabis-based Sativex
Article | 10 May 2004
UK firm GW Pharmaceutical has another delay in gaining domestic regulatory approval for Sativex oral spray, its cannabis-based multiple sclerosis ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
